Haplotypes in matrix metalloproteinase gene cluster on chromosome 11q22 contribute to the risk of lung cancer development and progression

Clinical Cancer Research

Volumn 12, Issue 23, 2006, Pages 7009-7017

  Sun, Tong ^a   Gao, Yang ^b   Tan, Wen ^a   Ma, Sufang ^b   Zhang, Xuemei ^a   Wang, Yonggang ^a   Zhang, Qingrun ^b   Guo, Yongli ^a   Zhao, Dan ^a   Zeng, Changqing ^b   Lin, Dongxin ^a  

^a CANCER HOSPITAL   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; STROMELYSIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CANCER STAGING; CHROMOSOME 11Q; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENE CLUSTER; GENE FREQUENCY; GENETIC TRANSCRIPTION; GENOTYPE; HAPLOTYPE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; CHROMOSOMES, HUMAN, PAIR 11; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; HAPLOTYPES; HUMANS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 12; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; MULTIGENE FAMILY; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS;

EID: 33845763846     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0464     Document Type: Article

References (56)

1. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis, and treatment selection. Nat Rev Cancer 2005;5:845-56.
2. Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 2004;4:850-60.
3. Neale BM, Sham PC. The future of association studies: gene-based analysis and replication. Am J Hum Genet 2004;75:353-62.
4. Thomas DC, Clayton DG. Betting odds and genetic associations. J Natl Cancer Inst 2004;96:421-3.
5. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet 2005;37:1217-23.
6. Johnson GC, Esposito L, Barratt BJ, et al. Haplotype tagging for the identification of common disease genes. Nat Genet 2001;29:233-7.
7. Bonnen PE, Wang PJ, Kimmel M, Chakraborty R, Nelson DL. Haplotype and linkage disequilibrium architecture for human cancer-associated genes. Genome Res 2002;12:1846-53.
8. Houwen L. State of the art: lung cancer in China. Ann Thorac Cardiovasc Surg 2003;9:147-8.
9. Zhang X, Miao X, Liang G, et al. Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res 2005;65:722-6.
10. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22:2594-601.
11. Wu X, Zhao H, Amos CI, et al. p53 Genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 2002;94:681-90.
12. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
13. Zhu Y, Spitz MR, Lei L, Mills GB, Wu X. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res 2001;61:7825-9.
14. Fang S, Jin X, Wang R, et al. Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China. Carcinogenesis 2005;26:481-6.
15. Zhou Y, Yu C, Miao X, et al. Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis 2005;26:1117-21.
16. Su L, Zhou W, Park S, et al. Matrix metalloproteinase-1 promoter polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:567-70.
17. Yu C, Pan K, Xing D, et al. Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res 2002;62:6430-3.
18. Zhang J, Jin X, Fang S, et al. The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma. Carcinogenesis 2005;26:1748-53.
19. Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 2004;64:7622-8.
20. Ghilardi G, Biondi ML, Mangoni J, et al. Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin Cancer Res 2001;7:2344-6.
21. Xu E, Lai M, Lu B, Xing X, Huang Q, Xia X. A single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer. Biochem Biophys Res Commun 2004;324:999-1003.
22. Zinzindohoue F, Lecomte T, Ferraz JM, et al. Prognostic significance of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer. Clin Cancer Res 2005;11:594-9.
23. Nishioka Y, Sagae S, Nishikawa A, Ishioka S, Kudo R. A relationship between matrix metalloproteinase-1 (MMP-1) promoter polymorphism and cervical cancer progression. Cancer Lett 2003;200:49-55.
24. Lai HC, Chu CM, Lin YW, et al. Matrixmetalloproteinase 1 gene polymorphism as a prognostic predictor of invasive cervical cancer. Gynecol Oncol 2005;96:314-9.
25. Pendas AM, Santamaria I, Alvarez MV, Pritchard M, Lopez-Otin C. Fine physical mapping of the human matrix metalloproteinase genes clustered on chromosome 11q22.3. Genomics 1996;37:266-8.
26. Berrieman HK, Ashman JN, Cowen ME, Greenman J, Lind MJ, Cawkwell L. Chromosomal analysis of non-small-cell lung cancer by multicolour fluorescent in situ hybridisation. Br J Cancer 2004;90:900-5.
27. Pan H, Califano J, Ponte JF, et al. Loss of heterozygosity patterns provide fingerprints for genetic heterogeneity in multistep cancer progression of tobacco smoke-induced non-small cell lung cancer. Cancer Res 2005;65:1664-9.
28. Michael M, Babic B, Khokha R, et al. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 1999;17:1802-8.
29. Nawrocki B, Polette M, Marchand V, et al. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantificative and morphological analyses. Int J Cancer 1997;72:556-64.
30. Cho NH, Hong KP, Hong SH, Kang S, Chung KY, Cho SH. MMP expression profiling in recurred stage IB lung cancer. Oncogene 2004;23:845-51.
31. Hofmann HS, Hansen G, Richter G, et al. Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients. Clin Cancer Res 2005;11:1086-92.
32. D'Armiento J, Dalal SS, Okada Y, Berg RA, Chada K. Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. Cell 1992;71:955-61.
33. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997;277:2002-4.
34. American Joint Committee on Cancer. AJCC cancer staging manual. 6th ed. New York (NY): Springer; 2002.
35. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological typing of lung and pleural tumors. 3rd ed. In: Travis WD, editor. WHO international histological classification of tumors. Berlin: Springer; 1999.
36. Buetow KH, Edmonson M, MacDonald R, et al. High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci U S A 2001;98:581-4.
37. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-9.
38. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
39. Qin ZS, Niu T, Liu JS. Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms. Am J Hum Genet 2002;71:1242-7.
40. Carlson CS, Eberle MA, Kruglyak L, Nickerson DA. Mapping complex disease loci in whole-genome association studies. Nature 2004;429:446-52.
41. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. Br Med J 1995;310:170.
42. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
43. Lake SL, Lyon H, Hantisira K, et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 2003;55:56-65.
44. Su L, Zhou W, Asomaning K, et al. Genotypes and haplotypes of matrix metalloproteinase 1, 3, and 12 genes and the risk of lung cancer. Carcinogenesis 2006;27:1024-9.
45. Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res 2000;6:4823-30.
46. Inoue T, Yashiro M, Nishimura S, et al. Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. Int J Mol Med 1999;4:73-7.
47. Baker EA, Bergin FG, Leaper DJ. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg 2000;87:1215-21.
48. Lin TS, Chiou SH, Wang LS, et al. Expression spectra of matrix metalloproteinases in metastasis non-small cell lung cancer. Oncol Rep 2004;12:717-23.
49. Sunami E, Tsuno N, Osada T, et al. MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist 2000;5:108-14.
50. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996;2:461-2.
51. Przybylowska K, Zielinska J, Zadrozny M, et al. An association between the matrix metalloproteinase 1 promoter gene polymorphism and lymphnode metastasis in breast cancer. J Exp Clin Cancer Res 2004;23:121-5.
52. Przybylowska K, Kluczna A, Zadrozny M, et al. Polymorphisms of the promoter regions of matrix metalloproteinase genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat 2006;95:65-72.
53. Sun J, Wiklund F, Zheng SL, et al. Sequence variants in Toll-like receptor gene cluster (TLR6-1-TLR10) and prostate cancer risk. J Natl Cancer Inst 2005;97:525-32.
54. Haiman CA, Stram DO, Pike MC, et al. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the multiethnic cohort. Hum Mol Genet 2003;12:2679-92.
55. Phillips MS, Lawrence R, Sachidanandam R, et al. Chromosome-wide distribution of haplotype blocks and the role of recombination hot spots. Nat Genet 2003;33:382-7.
56. Schmidt C. Latest HapMap update aims to direct researchers to genetic basis of disease. J Natl Cancer Inst 2005;97:1638-40.